Atea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting ® 2018
- AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor
- AT-527 shows profound and equivalent pan-genotypic antiviral activity in cirrhotic and non-cirrhotic (NC) hepatitis C virus (HCV) infected patients
- AT-527 was safe and well tolerated with once-daily (QD) dosing of 550 mg for 7 days
- Data support Phase 2 clinical development of AT-527
BOSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. The data will be presented on November 10, 2018 at The Liver Meeting® 2018 sponsored by the American Association for the Study of Liver Diseases taking place in San Francisco, California.
“Despite the introduction of direct acting antiviral therapies in recent years, hepatitis C continues to represent a serious global health burden, particularly among GT-3 infected, cirrhotic and other difficult-to-treat patient populations,” stated Jean-Pierre Sommadossi, PhD, Atea’s Founder, Chairman and Chief Executive Officer. “We are very excited about the clinical profile of AT-527, which has demonstrated significant antiviral potency in HCV-infected subjects, regardless of genotype or cirrhotic status. Based upon the results from our proof of concept clinical trial, we believe AT-527 may be the backbone of the first drug regimen that allows for 8-week treatment in both cirrhotic and non-cirrhotic patients. We look forward to advancing AT-527 into Phase II development in 2019.”
Poster No. 1002
AT-527, a purine nucleotide prodrug, exhibits potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis
Date/Time: Saturday, November 10, 2018; 2:00 pm – 7:30 pm PST
Location: Moscone Center North/South Building, Hall C
A summary of the data to be presented shows rapid and potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis, as in non-cirrhotic subjects, with a mean HCV reduction of 2.4 log10 IU/mL after a single dose and a mean maximum HCV RNA reduction of 4.6 log10 IU/mL after 7 days of dosing with AT-527 550 mg. Previously reported data also show a mean maximum HCV RNA reduction of 4.4 log10 IU/mL after 7 days of dosing of AT-527 550 mg in NC GT-1b HCV-infected subjects, and a mean reduction of 4.5 log10 IU/mL after 7 days of dosing was achieved in NC GT-3 HCV-infected subjects. No serious adverse events, dose-limiting toxicities or premature discontinuations were observed, and pharmacokinetic data (PK) in cirrhotic subjects was similar to non-cirrhotic subjects. Emax modeling demonstrated that a dose of 550 mg QD will result in maximum viral load reduction.
About the Trial
The five-part, Phase IB/IIA trial studied single and multiple doses of AT-527 in healthy and HCV-infected subjects. All HCV-infected subjects were treatment-naïve with HCV RNA ≥ 5 log10 IU/mL. The objectives of the study were to assess safety/tolerability, pharmacokinetics (PK) and antiviral activity.
The trial evaluated single oral doses up to 367 mg (400 mg salt form) in healthy subjects (Part A), single doses up to 550 mg (600 mg salt form) in NC GT-1b HCV-infected subjects (Part B) and multiple doses up to 550 mg once-daily (QD) for 7 days in NC GT-1b HCV-infected subjects (Part C). Additional cohorts evaluated 550 mg QD for 7 days in NC GT-3 (Part D) and CPA cirrhotic GT-1b/3 (Part E) HCV-infected subjects. Plasma levels of AT-273, the nucleoside metabolite of the active triphosphate, were measured using LC-MS/MS; HCV RNA was quantified using COBAS® AmpliPrep/TaqMan® HCV Test v2.0 with a limit of quantitation (LOQ) of 15 IU/mL.
AT-527, a proprietary investigational agent discovered at Atea, is the salt form of a purine nucleotide prodrug NS5B polymerase inhibitor. Unique structural modifications of AT-527 result in differentiated pharmacologic and antiviral properties as compared to other anti-HCV nucleotides. AT-511, the free base of AT-527, showed potent antiviral activity in vitro against wild-type clinical isolates with EC95 values less than 80 nM in all HCV genotypes, and demonstrated about 10- to 14-fold more potency than sofosbuvir (SOF) in GT-1 and GT-3 replicons. AT-511 maintained activity against SOF-resistant S282T single and S282T/L159F double variants, with about 50-fold greater potency than SOF.
About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and transplants. According to the World Health Organization, over 70 million people suffer from chronic hepatitis C. Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of many patients infected with the hepatitis C virus and allow the achievement of a cure in 8 – 12 weeks in select patient populations. Further shortening of the treatment duration in those patients and extending it to more difficult-to-treat HCV patient populations continues to be a sought-after goal of the biotech and pharma industry. Global sales of DAAs for the treatment of HCV infection are expected to exceed $8 billion in 2018.
Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in the discovery and development of proprietary and novel therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections. Atea was founded in 2013 by its Chairman and Chief Executive Officer Jean-Pierre Sommadossi, PhD, and is headquartered in Boston, MA.
Andrea J. Corcoran
Investors and Media:
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research15.11.2018 22:05 | Pressemelding
LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses NYBC becoming a long-term supplier of donor red blood cells (RBC) to ERYTECH, enabling ERYTECH to diversify and broaden its supply of RBC source materials for the production of eryaspase and future product candidates derived from its proprietary ERYCAPS® platform as the company ramps up clinical development. Specifically for the Phase 3 trial in second-line metastatic pancreatic cancer that recently started enrolling patients in Europe, and the Phase 2 trial in first-line triple negative breast cancer (TNBC), which are both expected to begin enrollment in the United States early in 2019. The partnershi
Zageno Deepens Engagement with Scientists and Vendors through Its Meaningful and Unbiased Rating System for Scientific Products — Scientific Score gets Algorithm Update15.11.2018 15:37 | Pressemelding
Call for Contributions: Zageno’s rating system for scientific products — the Scientific Score — adds a crucial dimension to help research scientists purchase the right material for their experiment. Scientists: share your experimental data and professional experience about products; Life Science Vendors: provide additional product-specific resources and data points to make your products reach the right scientist CAMBRIDGE, Mass. USA and BERLIN, Germany, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., the largest and fastest-growing online marketplace for research materials, today issues an open call for scientists and vendors alike to contribute to the continuous improvement of the Scientific Score. Designed as an unbiased indicator to help purchasing scientists navigate the enormous amount of product information, the Scientific Score is the result of proprietary algorithms calculating and weighing different data points across multiple information formats. Among others, factors like rec
SignalFx Delivers Next Generation of Application Performance Monitoring15.11.2018 15:00 | Pressemelding
The first to enable directed troubleshooting for applications and microservices SAN MATEO, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring for infrastructure, microservices, and applications, today unveiled SignalFx Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate troubleshooting for DevOps teams through advanced real-time analytics. Powered by NoSample™ distributed tracing architecture, SignalFx Microservices APM observes every single transaction – not just a small random sample – and reports on every anomaly. With the new Outlier Analyzer™, the most challenging issues can now be pinpointed and resolved with a single click. SignalFx Microservices APM is built on top of SignalFx’s advanced streaming analytics platform for metrics which applies unsurpassed data science in real-time to identify the root cause of critical application problems. Integration with advanced automat
Motiv Ring Expands International Footprint and Delivers Industry-First Sizing Process15.11.2018 15:00 | Pressemelding
The wearable ring lands in 20 new countries and eight new stores, and introduces frictionless sizing method SAN FRANCISCO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Motiv Inc., creators of breakthrough wearable technology, today announced an increase of its product availability through new international availability and a new digital sizing set alternative. Motiv Ring’s international expansion will be through its website MyMotiv.com. Featured countries include: North America (Canada), Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Latvia, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, Norway and Switzerland), as well as Japan, Taiwan, Turkey, Australia and New Zealand. Good fit is imperative to great functionality. To date, Motiv Ring users select their sizes after receiving a physical sizing kit in the mail. Releasing in Open Beta , Motiv Ring users will now have the additional option of determining their Motiv size via a
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 201815.11.2018 14:30 | Pressemelding
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases WALTHAM, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader. Discussions will feature the following speakers and topics: Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Depa
New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments15.11.2018 14:00 | Pressemelding
Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently published in the Journal of Visual Experiments the establishment and immunological characterization of PDAC orthotopic tumor homograft models. Pancreatic ductal adenocarcinoma (PDAC) research represents an area of high unmet medical need. PDAC fails to respond to a range of cancer therapies, including immunotherapy, partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment. The development of new therapeutic and combination strategies requires highly relevant preclinical models recapitulating the complexity of PDAC tumors including the TME. Transplantable PDAC models, developed by pass
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom